Dolutegravir Expanded Access Study (DEAP)
A Dolutegravir Open Label Protocol for HIV Infected, Adult and Adolescent Patients With Integrase Resistance
Sponsor: GlaxoSmithKline
This NA trial investigates HIV Infections and Infection, Human Immunodeficiency Virus and is currently completed. GlaxoSmithKline leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Oct 2020 — Jan 2021 [monthly]
Completed NA
Status: Unknown Status → Completed · Phase: PHASE3 → NA
▶ Show 4 earlier versions
-
Feb 2019 — Oct 2020 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- ViiV Healthcare
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Antwerp, Belgium , Atlanta, United States , Austin, United States , Bagno A Ripoli (FI), Italy , Bonn, Germany , Bordeaux, France , Brussels, Belgium , Chapel Hill, United States , Chicago, United States , Cologne, Germany and 50 more locations